Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: Long-term experiences at the Rotterdam family cancer clinic

Annals of Surgical Oncology

Volumn 14, Issue 12, 2007, Pages 3335-3344

  Heemskerk Gerritsen, Bernadette A M ^a   Brekelmans, Cecile T M ^a   Menke Pluymers, Marian B E ^a   Van Geel, Albert N ^a   Tilanus Linthorst, Madeleine M A ^a   Bartels, Carina C M ^a   Tan, Murly ^a   Meijers Heijboer, Hanne E J ^a,b   Klijn, Jan G M ^a   Seynaeve, Caroline ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1 2; Breast cancer; Complications; Mastectomy; Prevention; Unexpected carcinomas

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; BREAST RECONSTRUCTION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; DIAGNOSTIC IMAGING; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; METASTASIS; ONCOGENE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PROPHYLACTIC MASTECTOMY; SECOND LOOK SURGERY;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MAMMAPLASTY; MASTECTOMY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NETHERLANDS; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 36348972261     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9449-x     Document Type: Article

References (36)

1. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-6
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62:676-89
3. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401-8
4. Bergfeldt K, Rydh B, Granath F, Gronberg H, Thalib L, Adami HO, Hall P. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet 2002; 360:891-4
5. Meijers-Heijboer H, van Geel B, Van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159-164
6. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055-62
7. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93:1633-7
8. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340:77-84
9. Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005; 97:476-82
10. Rosen B, Kwon J, Fung Kee FM, Gagliardi A, Chambers A. Systematic review of management options for women with a hereditary predisposition to ovarian cancer. Gynecol Oncol 2004; 93:280-6
11. van Geel AN, Contant CM, Tjong Joe Wai R, Schmitz PI, Eggermont AM, Menke-Pluijmers MM. Mastectomy by inverted drip incision and immediate reconstruction: data from 510 cases. Ann Surg Oncol 2003; 10:389-95
12. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000; 355:2015-20
13. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003; 21:1675-81
14. Klijn JGM, van Geel B, Meijers-Heijboer H, et al. Results of the extended series on prophylactic mastectomy versus surveillance in BRCA1/2 mutation carriers in Rotterdam. Breast Cancer Res Treat 2004; 88[S10]. Ref Type: Abstract
15. Contant CM, Menke-Pluijmers MB, Seynaeve C, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol 2002; 28:627-32
16. Bresser PJ, Seynaeve C, Van Gool AR, et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg 2006; 117:1675-82
17. Verhoog LC, van den Ouweland AM, Berns E, et al. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 2001; 37:2082-90
18. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351:316-21
19. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999; 17:3396-3402
20. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-5
21. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22:2328-35
22. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998; 16:1642-9
23. Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000; 83:384-6
24. Shahedi K, Emanuelsson M, Wiklund F, Gronberg H. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer 2006; 106:1237-42
25. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005; 41:2304-11
26. Tilanus-Linthorst MM, Bartels KC, Alves C, et al. Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients. Breast Cancer Res Treat 2006; 95:117-23
27. Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, Phillips KA. Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet 2003; 64:111-21
28. Khurana KK, Loosmann A, Numann PJ, Khan SA. Prophylactic mastectomy: pathologic findings in high-risk patients. Arch Pathol Lab Med 2000; 124:378-81
29. Hoogerbrugge N, Bult P, Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003; 21:41-5
30. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427-37
31. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469-76
32. Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 2006; 107:1440-7
33. Contant CM, van Geel AN, van der Holt B, Griep C, Tjong Joe Wai R, Wiggers T. Morbidity of immediate breast reconstruction (IBR) after mastectomy by a subpectorally placed silicone prosthesis: the adverse effect of radiotherapy. Eur J Surg Oncol 2000; 26:344-50
34. Lin KY, Johns FR, Gibson J, Long M, Drake DB, Moore MM. An outcome study of breast reconstruction: presurgical identification of risk factors for complications. Ann Surg Oncol 2001; 8:586-91
35. Zion SM, Slezak JM, Sellers TA, et al. Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer 2003; 98:2152-60
36. Barton MB, West CN, Liu IL, et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr 2005;61-6